BioDrugs

, Volume 20, Issue 5, pp 313–316 | Cite as

Human Papillomavirus Quadrivalent (types 6,11, 16,18) Recombinant Vaccine (Gardasil®): Profile Report

Adis Profile Report

Keywords

Cervical Cancer Cervical Intraepithelial Neoplasia Genital Wart Invasive Cervical Cancer Cervical Cancer Prevention 

References

  1. 1.
    Siddiqui MAA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil®). Drugs 2006; 66(9): 1263–71PubMedCrossRefGoogle Scholar
  2. 2.
    Ferris DG. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a viewpoint by Daron G. Ferris. Drugs 2006; 66(9): 1272CrossRefGoogle Scholar
  3. 3.
    Fife KH. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a viewpoint by Kenneth H. Fife. Drugs 2006; 66(9): 1272–3CrossRefGoogle Scholar
  4. 4.
    Ault KA. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a viewpoint by Kevin A. Ault. Drugs 2006; 66(9): 1273Google Scholar
  5. 5.
    Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: cancer incidence, mortality and prevalence. Worldwide IARC CancerBase no. 5. version 2.0. Lyon: IARC Press, 2004Google Scholar
  6. 6.
    National Cancer Institute. Cervical cancer physician data query (PDQ®): screening (health professional version) [online]. Available from URL: http://cancer.gov/ [Accessed 2006 Apr 5]
  7. 7.
    Sirovich BE, Welch HG. The frequency of Pap smear screening in the United States. J Gen Intern Med 2004 Mar; 19(3): 243–50PubMedCrossRefGoogle Scholar
  8. 8.
    National Cancer Institute. Cervical cancer physician data query (PDQ®): prevention (health professional version) [online]. Available from URL: http://cancer.gov/ [Accessed 2006 Apr 5]
  9. 9.
    American Cancer Society. Cancer facts & figures 2006 [online]. Available from URL: http://www.cancer.org/ [Accessed 2006 Apr 5]
  10. 10.
    Bosch FX, de Sanjose S. Chapter 1: human papillomavirus and cervical cancerburden and assessment of causality. J Natl Cancer Inst Monogr 2003; 31: 3–13PubMedCrossRefGoogle Scholar
  11. 11.
    The National Center for HIV, STD, and TB Prevention. Genital HPV infection [online]. Available from URL: http://www.cdc.gov/ [Accessed 2006 Apr 5]CrossRefGoogle Scholar
  12. 12.
    Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005 Mar 18; 23(17–18): 2388–94PubMedCrossRefGoogle Scholar
  13. 13.
    Jansen KU, Shaw AR. Human papillomavirus vaccines and prevention of cervical cancer. Annu Rev Med 2004; 55: 319–31PubMedCrossRefGoogle Scholar
  14. 14.
    Clifford GM, Rana RK, Franceschi S, et al. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005 May; 14(5): 1157–64PubMedCrossRefGoogle Scholar
  15. 15.
    Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004 Aug 20; 111(2): 278–85Google Scholar
  16. 16.
    Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005 May; 6(5): 271–8PubMedCrossRefGoogle Scholar
  17. 17.
    Fife KH, Wheeler CM, Koutsky LA, et al. Dose-ranging studies of the safety and immunogenicity of human papillomavirus type 11 and type 16 virus-like particle candidate vaccines in young healthy women. Vaccine 2004 Jul 29; 22(21-22): 2943–52PubMedCrossRefGoogle Scholar
  18. 18.
    Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003 Aug 13; 290(6): 781–9PubMedCrossRefGoogle Scholar
  19. 19.
    Elbasha EH, Dasbach EJ, Insinga RP. Projecting the health and economic impact of a quadrivalent HPV vaccine using a multi-type transmission dynamic model [abstract. The 40th National Immunization Conference; 2006 Mar 6–9; Atlanta (GA)Google Scholar
  20. 20.
    Tobery TW, Smith JF, Kuklin N, et al. Effect of vaccine delivery system on the induction of HPV16 L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques. Vaccine 2003 Mar 28; 21(13-14): 1539–47PubMedCrossRefGoogle Scholar
  21. 21.
    Merck & Co. Inc. Product information (US): Gardasil® (quadrivalent human papillomavirus [types 6, 11, 16, 18] recombinant vaccine) [online]. Available from URL: http://www.fda.gov/cber/label/hpvmer060806LB.pdf [Accessed 2006 Jun 12]
  22. 22.
    Ruiz W, McClements WL, Jansen KU, et al. Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6,11,16and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant. J Immune Based Ther Vaccines 2005 Apr 20; 3(1): 2–12PubMedCrossRefGoogle Scholar
  23. 23.
    Villa LL, Costa RLR, Petta CA. Induction of immune memory following administration of a prophylactic quadrivalent Human Papillomavirus (HPV) types 6/11/ 16/18 L1 virus-like particle (VLP) vaccine [abstract]. The 12th International Congress on Infectious Diseases; 2006 Jun 15–18; LisbonGoogle Scholar
  24. 24.
    Nolan T, Block SL, Reisinger KS, et al. Comparison of the immunogenicity and tolerability of a prophylactic quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine in male and female adolescents and young adult women [abstract]. The 23rd Annual Meeting of the European Society of Paediatric Infectious Diseases; 2005 May 18–20; ValenciaGoogle Scholar
  25. 25.
    Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002 Nov 21; 347: 1645–51PubMedCrossRefGoogle Scholar
  26. 26.
    Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006 Jan; 107(1): 18–27PubMedCrossRefGoogle Scholar
  27. 27.
    Poland GA, Jacobson RM, Koutsky LA, et al. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial. Mayo Clin Proc 2005 May; 80(5): 601–10PubMedCrossRefGoogle Scholar
  28. 28.
    Ault KA, Giuliano AR, Edwards RP, et al. A phase I study to evaluate a human papillomavirus (HPV) type 18 LI VLP vaccine. Vaccine 2004 Aug 13; 22(23-24): 3004–7PubMedCrossRefGoogle Scholar
  29. 29.
    Reisinger KS, Block SL, Lazcano E, et al. A randomized controlled trial to evaluate the safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in preadolescents and adolescents [abstract]. The 24th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2006 May 3–5; BaselGoogle Scholar
  30. 30.
    Sattler C, Future 1 Investigators. Efficacy of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine for prevention of cervical dysplasia and external genital lesions [abstract no. LB2-25]. The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16–19; Washington, DCGoogle Scholar
  31. 31.
    Skjeldestad FE, Future II Steering Committee. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine (Gardasil™) reduces cervical intraepithelial neoplasia 2/3 risk [abstract no. LB-8]. The 43rd Annual Meeting of the Infectious Diseases Society of America; 2005 Oct 6–9; San Francisco (CA)Google Scholar
  32. 32.
    Ault K, on behalf of the ia]Gardasil™ Phase III Steering Committee. Prophylactic use of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine reduces cervical intraepithelial neoplasia 2/3 and adenocarcinoma in situ risk [abstract no. PS10]. Eur J Can Suppl 2005; 3(4): 11. Plus oral presentation at the European Cancer Conference; 2005 Oct 30-Nov 3; ParisCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Wolters Kluwer Health, AdisMairangi Bay, AucklandNew Zealand
  2. 2.editorial office of Wolters Kluwer HealthConshohockenUSA

Personalised recommendations